The earnings call presented a strong performance with significant revenue growth in Testing Services and advancements in kidney testing. Operational improvements and the launch of AlloSure Plus are positive indicators. However, there are concerns related to the revenue write-off and potential financial impacts of the draft LCD policy.

Company Guidance

During the CareDx Second Quarter 2025 Earnings Call, the company provided several financial metrics and projections. Adjusted revenue for the quarter was reported at $90.5 million, marking a 14% year-over-year increase. Adjusted EBITDA was $9.1 million, a significant improvement from a $300,000 loss in the same period last year. The company reaffirmed the midpoint of its 2025 revenue guidance, narrowing the range to $367 million to $373 million, and maintained expectations for adjusted EBITDA of $29 million to $33 million. Testing Services revenue reached $66 million, with 49,500 tests delivered, reflecting a 13% increase in testing volume year-over-year. The company also highlighted progress in kidney testing, noting a nearly 20% growth, and introduced AlloSure Plus, an AI-driven diagnostic for kidney transplant monitoring. The call addressed potential headwinds from a draft LCD policy, estimating a $15 million to $30 million impact depending on the final policy's implementation. Additionally, the company reported operational improvements, including a 60% reduction in claim submission time and a 45% increase in prior authorization success rate.

Strong Revenue Growth in Testing Services

Adjusted Testing Services revenue was $66 million, up 14% year-over-year, with a delivery of approximately 49,500 tests, marking the eighth consecutive quarter of sequential testing volume growth.

Significant Advancements in Kidney Testing

Kidney testing volume grew nearly 20% year-over-year, surpassing 60 surveillance protocols nationally.

Introduction of AlloSure Plus

Launch of AlloSure Plus, an AI-driven diagnostic to deliver a personalized risk score of rejection, integrating AlloSure results with standard care measures.

Operational Excellence Initiatives

Improvements in revenue cycle management, including a 60% reduction in claim submission time and a 45% increase in prior authorization success rate.

Growth in Patient & Digital Solutions

Reported revenue of $12.8 million, representing 19% growth compared to the previous year.

CareDx (CDNA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CDNA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-0.08 / -	-0.14	―	―	―
Aug 06, 2025	2025 (Q2)	-0.10 / -0.16	-0.03	-433.33% (-0.13)
Apr 30, 2025	2025 (Q1)	-0.21 / -0.19	-0.32	40.63% (+0.13)
Feb 26, 2025	2024 (Q4)	-0.41 / 1.51	-2.21	168.33% (+3.72)
Nov 04, 2024	2024 (Q3)	-0.25 / -0.14	-0.43	67.44% (+0.29)
Jul 31, 2024	2024 (Q2)	-0.40 / -0.03	-0.46	93.48% (+0.43)
May 09, 2024	2024 (Q1)	-0.47 / -0.32	-0.44	27.27% (+0.12)	―
Feb 28, 2024	2023 (Q4)	-0.45 / -2.21	-0.34	-550.00% (-1.87)	―
Nov 08, 2023	2023 (Q3)	-0.59 / -0.43	-0.32	-34.37% (-0.11)	―
Aug 08, 2023	2023 (Q2)	-0.55 / -0.46	-0.41	-12.20% (-0.05)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CDNA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$13.10	$12.07	-7.86%
Apr 30, 2025	$16.88	$15.07	-10.72%
Feb 26, 2025	$21.10	$21.06	-0.19%
Nov 04, 2024	$22.93	$22.90	-0.13%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.